CHD

Business Context and Reporting Period

Company: Church & Dwight Co., Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 30, 2007
Business Overview: The Company manufactures and markets household and personal care products (e.g., ARM & HAMMER, OXICLEAN, TROJAN) and specialty chemical products. Operations are organized into three segments: Consumer Domestic, Consumer International, and Specialty Products Division (SPD). A significant portion of the current period's results reflects the integration of the Orange Glo International, Inc. (OGI) business acquired in late 2006.

Key Financial Metrics

Note: Total Debt calculated as Short-term borrowings ($115,350) + Current portion of long-term debt ($35,705) + Long-term debt ($755,827).

Material Changes vs. Prior Period

• Revenue Growth: Net sales increased 16.3% ($71.9 million) year-over-year. This was driven primarily by $57.1 million in sales from the OGI acquisition, $3.9 million from favorable foreign exchange rates, and the full inclusion of SPINBRUSH business revenues (which were previously recorded as other revenue).
• Profitability: Gross margin expanded 70 basis points to 38.9%, aided by price increases implemented in 2006, higher margins from OGI, and cost reduction programs offsetting raw material inflation. Net income rose 12.9% to $45.1 million.
• Expenses: Marketing expenses increased $12.5 million due to OGI product support and personal care initiatives. SG&A expenses rose $8.5 million, attributed to OGI integration costs, higher stock-based compensation, and legal fees.
• Interest Expense: Increased $3.9 million due to higher debt levels incurred to fund the OGI acquisition and rising interest rates.
• Tax Rate: The effective tax rate decreased to 36.0% from 39.7%, largely due to the reinstatement of the research and development tax credit in late 2006.

Guidance, Outlook, and Risks

• Outlook: Management anticipates increasing marketing expenses in the second quarter of 2007 to support new product launches. Operating cash flows are expected to be sufficient for the remainder of the year.
• Debt Covenants: The Company remains in compliance with its credit facility covenants. The leverage ratio (Total Debt to Adjusted EBITDA) was 2.57x (limit 4.00x), and the interest coverage ratio was 6.08x (minimum 3.0x) for the trailing twelve months.
• Legal Contingencies:
  • Andes Trading Litigation: The Company settled a distribution rights dispute in Mexico on April 11, 2007, paying $10.4 million (including accrued interest) following an appellate court decision upholding a reduced verdict.
  • FDA Regulation: Ongoing uncertainty regarding FDA labeling requirements for condoms containing nonoxynol-9 (N-9). While the Company has implemented interim labeling, future restrictions could impact sales and incur costs for obsolete inventory.
• Accounting Changes: The Company adopted FIN 48 (Accounting for Uncertainty in Income Taxes) on January 1, 2007, resulting in an $8.3 million increase in the liability for unrecognized tax benefits and a $2.5 million cumulative effect adjustment to retained earnings.

Investor Verification Checklist

• OGI Integration: Verify the progress of transferring OGI manufacturing to existing plants and the realization of projected synergies.
• Debt Servicing: Monitor the impact of floating interest rates on the $906.9 million debt load, particularly given the $3.1 million annual exposure to a 10% rate change.
• Regulatory Compliance: Track FDA final guidance on N-9 condom labeling to assess potential revenue impact on the Trojan brand.
• Working Capital: Review inventory levels ($214.4 million), which increased $20.2 million due to OGI transition and promotional stockpiling, to ensure efficient turnover.
• Tax Position: Monitor the $18.4 million in unrecognized tax benefits and potential changes resulting from audit settlements.